RGNX REGENXBIO Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RGNX

Price (delayed)

$16.83

Market cap

$747.72M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.02

Enterprise value

$800.45M

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, ...

Highlights
RGNX's EPS is up by 7% year-on-year
REGENXBIO's debt has decreased by 6% YoY
The gross margin has increased by 14% year-on-year but it has declined by 3.6% since the previous quarter
The equity has contracted by 40% YoY and by 14% from the previous quarter
The quick ratio has declined by 24% year-on-year and by 11% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.regenxbio.com
Peers: OMER OMGA

Key stats

What are the main financial stats of RGNX
Market
Shares outstanding
44.43M
Market cap
$747.72M
Enterprise value
$800.45M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.37
Price to sales (P/S)
8.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.87
Earnings
Revenue
$90.24M
EBIT
-$256.78M
EBITDA
-$239.46M
Free cash flow
-$228.37M
Per share
EPS
-$6.02
Free cash flow per share
-$5.22
Book value per share
$7.09
Revenue per share
$2.06
TBVPS
$13.12
Balance sheet
Total assets
$573.97M
Total liabilities
$262.23M
Debt
$89.29M
Equity
$311.74M
Working capital
$204.7M
Liquidity
Debt to equity
0.29
Current ratio
2.57
Quick ratio
2.32
Net debt/EBITDA
-0.22
Margins
EBITDA margin
-265.4%
Gross margin
58.8%
Net margin
-292%
Operating margin
-297.1%
Efficiency
Return on assets
-40%
Return on equity
-68.2%
Return on invested capital
-45%
Return on capital employed
-57.9%
Return on sales
-284.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RGNX stock price

How has the REGENXBIO stock price performed over time
Intraday
1.14%
1 week
3.95%
1 month
-16.89%
1 year
-16.81%
YTD
-6.24%
QTD
-20.12%

Financial performance

How have REGENXBIO's revenue and profit performed over time
Revenue
$90.24M
Gross profit
$53.03M
Operating income
-$268.13M
Net income
-$263.49M
Gross margin
58.8%
Net margin
-292%
RGNX's operating margin is down by 27% year-on-year and by 13% since the previous quarter
The company's revenue fell by 20% YoY and by 9% QoQ
REGENXBIO's net margin has decreased by 17% YoY and by 11% QoQ
The gross margin has increased by 14% year-on-year but it has declined by 3.6% since the previous quarter

Growth

What is REGENXBIO's growth rate over time

Valuation

What is REGENXBIO stock price valuation
RGNX P/E details
P/E
N/A
P/B
2.37
P/S
8.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.87
RGNX's EPS is up by 7% year-on-year
The equity has contracted by 40% YoY and by 14% from the previous quarter
RGNX's P/B is 13% above its last 4 quarters average of 2.1 but 12% below its 5-year quarterly average of 2.7
The price to sales (P/S) is 38% lower than the 5-year quarterly average of 13.2
The company's revenue fell by 20% YoY and by 9% QoQ

Efficiency

How efficient is REGENXBIO business performance
The ROE is down by 46% YoY and by 15% QoQ
The ROIC has contracted by 33% YoY and by 11% from the previous quarter
REGENXBIO's ROA has decreased by 32% YoY and by 11% from the previous quarter
RGNX's return on sales is down by 25% year-on-year and by 13% since the previous quarter

Dividends

What is RGNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RGNX.

Financial health

How did REGENXBIO financials performed over time
RGNX's total assets is 119% greater than its total liabilities
RGNX's total assets is down by 31% year-on-year and by 9% since the previous quarter
The quick ratio has declined by 24% year-on-year and by 11% since the previous quarter
REGENXBIO's debt is 71% lower than its equity
RGNX's debt to equity has soared by 61% year-on-year and by 16% since the previous quarter
The equity has contracted by 40% YoY and by 14% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.